#67
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Cannabinoid hyperemesis syndrome (CHS) is an emerging clinical condition that clinicians need to recognize and diagnose in patients presenting with recurrent nausea and vomiting associated with chronic cannabis use. Understanding CHS is critical because the condition’s symptoms can mimic other gastrointestinal disorders, leading to unnecessary diagnostic testing and delayed appropriate management, which typically involves cannabis cessation. As cannabis legalization expands access and use increases, clinicians should screen for cannabis use patterns in patients with intractable nausea and vomiting to distinguish CHS from other conditions and provide evidence-based counseling about this under-recognized adverse effect.
Cannabinoid hyperemesis syndrome (CHS) is an increasingly recognized clinical condition affecting frequent, long-term cannabis users who present with cyclic severe nausea, vomiting, and abdominal pain that paradoxically improves with hot showers or baths. As cannabis use becomes more prevalent and potency increases due to legalization and commercial cultivation, clinicians should maintain heightened suspicion for CHS in patients with refractory nausea and vomiting, particularly those with heavy cannabis consumption histories, since the condition is often misdiagnosed and leads to unnecessary diagnostic testing and emergency department visits. The pathophysiology likely involves dysregulation of cannabinoid receptors in the gastrointestinal tract, though the exact mechanisms remain incompletely understood, limiting therapeutic options beyond cannabis cessation. Early recognition and counseling patients on cannabis discontinuation is critical, as CHS can significantly impair quality of life and increase healthcare utilization costs. Clinicians should screen for cannabis use patterns in patients presenting with cyclical gastrointestinal symptoms and educate them that continued use despite symptoms will perpetuate the condition. Patient awareness of this syndrome may improve treatment adherence and reduce unnecessary emergency care among heavy cannabis users experiencing these symptoms.
“We’re seeing cannabinoid hyperemesis syndrome reported more frequently in our clinics, and while the underlying mechanism isn’t fully understood yet, the clinical pattern is real enough that we need to screen for it in patients presenting with chronic nausea and heavy cannabis use, particularly those using high-potency products.”
🏥 Cannabinoid hyperemesis syndrome (CHS) represents an emerging clinical entity that warrants increased recognition among providers managing patients with chronic cannabis use, particularly as product potency and consumption frequency continue to escalate in legalized markets. The syndrome’s pathophysiology remains incompletely understood, with proposed mechanisms involving cannabinoid receptor overstimulation in the enteric nervous system, though individual variation in metabolism and genetic predisposition likely contribute to variable presentation and severity. Clinicians should be aware that CHS can mimic other gastrointestinal disorders, potentially leading to unnecessary investigations and delayed diagnosis, while also recognizing that cessation of cannabis remains the only reliably effective treatment despite patients’ frequent reluctance to discontinue. The expanding use of high-potency concentrates and edibles among chronic users appears to increase CHS incidence, making this a relevant concern for primary care and emergency medicine encounters. Given the prevalence of cannabis
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
